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Abstract Antinuclear autoantibodies (ANAs) displaying
the nuclear dense fine speckled immunofluorescence (DFS-
IIF) pattern in HEp-2 substrates are commonly observed in
clinical laboratory referrals. They target the dense fine
speckled autoantigen of 70 kD (DFS70), most commonly
known as lens epithelium-derived growth factor p75
(LEDGFp75). Interesting features of these ANAs include
their low frequency in patients with systemic autoimmune
rheumatic diseases (SARD), elevated prevalence in
apparently healthy individuals, IgG isotype, strong trend to
occur as the only ANA specificity in serum, and occurrence
in moderate to high titers. These autoantibodies have also
been detected at varied frequencies in patients with diverse
non-SARD inflammatory and malignant conditions such as
atopic diseases, asthma, eye diseases, and prostate cancer.
These observations have recently stimulated vigorous
research on their clinical and biological significance. Some
studies have suggested that they are natural, protective
antibodies that could serve as biomarkers to exclude a
SARD diagnosis. Other studies suggest that they might be
pathogenic in certain contexts. The emerging role of
DFS70/LEDGFp75 as a stress protein relevant to human
acquired immunodeficiency syndrome, cancer, and
inflammation also points to the possibility that these
autoantibodies could be sensors of cellular stress and
inflammation associated with environmental factors. In this
comprehensive review, we integrate our current knowledge
of the biology of DFS70/LEDGFp75 with the clinical
understanding of its autoantibodies in the contexts of health
and disease.
Keywords Antinuclear autoantibodies  Autoimmunity 




AIDS Acquired immunodeficiency syndrome
ANAs Antinuclear autoantibodies
CFS Chronic fatigue syndrome
DFS Dense fine speckles
DFS70 Dense fine speckled autoantigen of 70 kD
DFS70-CIA DFS70 chemiluminescence assay
DM Dermatomyositis
ELISA Enzyme-linked immunosorbent assay
FM Fibromyalgia
HDGF Hepatoma derived growth factor
HI Healthy individuals
HIV Human immunodeficiency virus
HIV-IN Human immunodeficiency virus integrase
HLA Human leukocyte antigen
HRP-2 HDGF-related protein 2
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ILD Interstitial lung disease
IHC Immunohistochemistry
IIF Indirect immunofluorescence microscopy
LEC Lens epithelium cells
LEDGFp75 Lens epithelium-derived growth factor
protein of 75 kD
LMP Lysosomal membrane permeabilization
miRNA Micro RNA
MLL Mixed leukemia lineage
PCa Prostate cancer
PSIP1 PC4 and SFRS1 interacting protein 1
PWWP Proline-tryptophan-tryptophan-proline motif
SARD Systemic autoimmune rheumatic disease
SFRS1 Serine/arginine-rich splicing factor 1




A hallmark of systemic autoimmune rheumatic diseases
(SARD) such as systemic lupus erythematosus (SLE) and
scleroderma is the presence of circulating, high-titer IgG
autoantibodies targeting nuclear and cytoplasmic autoanti-
gens of protein or nucleic acid nature [1]. These ‘‘antinuclear
autoantibodies’’ (ANAs), are typically detected by indirect
immunofluorescence (IIF) microscopy in commercially
available HEp-2 ANA test slides and have been extensively
used as biomarkers in the differential diagnosis of SARD
and molecular probes for the discovery and characterization
of novel intracellular autoantigens [1]. They can also be
detected in non-SARD conditions such as cancer and are
considered as ‘‘messengers’’ or ‘‘reporters’’ of molecular and
cellular events that induce an autoimmune response [1, 2].
Autoantibodies targeting the nuclear autoantigen DFS70/
LEDGFp75 have attracted much interest given their rela-
tively common occurrence in patient sera referred to clinical
laboratories for ANA-HEp-2 testing [3–7]. While DFS70/
LEDGFp75 has emerged as a multifunctional stress response
protein of high relevance to acquired immunodeficiency
syndrome (AIDS), cancer, inflammation and other human
conditions [8–12], several unanswered questions concerning
the clinical and biological significance of its associated
autoantibodies still remain. Why are high-titer anti-DFS70/
LEDGFp75 autoantibodies common among patients with
positive ANA tests who are asymptomatic for SARD? Are
there differences in the frequencies and clinical associations
of these autoantibodies in young versus older people? What
makes DFS70/LEDGFp75 immunogenic in some apparently
healthy individuals (HI) and patients with non-SARD
inflammatory conditions? Are these antibodies protective,
pathogenic, or sensors of underlying inflammatory patholo-
gies? Do all human sera positive for autoantibodies recog-
nizing the nuclear dense fine speckled immunofluorescence
pattern (DFS-IIF) specifically target DFS70/LEDGFp75? In
the following sections, we address these questions while
integrating our basic and clinical knowledge of this
autoantigen-autoantibody system.
Discovery of DFS70/LEDGFp75
A timeline of key milestones in the discovery and charac-
terization of the DFS70/LEDGFp75 autoantigen-autoanti-
body system is presented in Table 1. The DFS70
autoantigen was originally identified in the 1990s during
surveys of ANAs in patients with interstitial cystitis (IC) and
chronic fatigue syndrome (CSF) [3, 4]. Using a high-titer
serum from an IC patient producing a strong DFS-IIF pat-
tern, a complementary DNA expression library was screened
and a partial DNA sequence for DFS70 was obtained [3].
This sequence was deposited in GenBank in 1997, and no
other sequence match was detected at the time [3]. When the
complete DFS70 sequence was later entered into GenBank,
it was found to be identical to a newly discovered gene
named transcription coactivator p75 (TCp75) and
LEDGFp75 [3, 13, 14]. TCp75 and its shorter splicing
variant p52 were identified as transcription coactivators of
the RNA polymerase II complex [13], whereas LEDGFp75
was identified as a lens epithelium cell (LEC)-derived
autoantigen targeted by autoantibodies in a patient with
cataracts [9, 14]. Initial studies suggested that LEDGFp75
was a growth factor in LECs [9, 14, 15]; however, it is now
recognized that this protein is ubiquitously present in
mammalian cells, playing roles more consistent with stress
protection than growth factor function. The gene encoding
this autoantigen is also designated PSIP1 (PC4 and SFRS1
interacting protein 1) [16], although the names DFS70 and
LEDGFp75 are the most commonly used for the protein.
Following the initial discovery of DFS70/LEDGFp75, three
independent groups made the seminal discovery that this
protein is a key cellular co-factor for HIV-1 integration into
host chromatin [17–20].
General properties of anti-DFS70/LEDGFp75
autoantibodies
These autoantibodies are predominantly IgG, often reaching
high titers in healthy individuals and patients with diverse
inflammatory diseases [3, 21–26]. They recognize a protein
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of 70–75 kD on immunoblots (predicted molecular size of
60 kD) that can be visualized by IIF microscopy as dense
fine speckles in the nucleoplasm of cells in interphase,
typically excluding the nucleolus, with increased staining
intensity of condensed mitotic chromosomes [3–6] (Fig. 1).
Muro and colleagues observed that very few patients with
SARD produce these antibodies, and usually in combination
with other SARD-marker autoantibodies such as anti-DNA,
anti-p80 coilin, and anti-topo I [27, 28]. They also showed
increased frequencies of human leukocyte antigen (HLA)-
DRB1, (HLA)-DQB1, and (HLA)-DPB1 alleles in patients
with anti-DFS70/LEDGFp75 antibodies, although a strong
correlation between these autoantibodies and specific HLA
alleles could not be established [29].
DFS70/LEDGFp75 structure and function
Gene and spliced variants
DFS70/LEDGFp75 and its short splice variant LEDGF/p52
(hereafter referred to as p52) (Fig. 2a) are derived from the
same PS1P1/LEDGF gene, which consists of 15 exons and
14 introns, with exons 1–15 encoding DFS70/LEDGFp75,
and exons 1–9 and a small part of intron 9 (24 nucleotides)
encoding p52 [30]. Although other alternatively spliced
variants of this gene have been identified [31], DFS70/
LEDGFp75 and p52 are the most common based on
immunoblotting analysis of cell lysates (Fig. 2b) [32–34].
DFS70/LEDGFp75 and p52 share an amino (N)-terminal
region (residues 1–325); however, p52 has an intron-
derived C-terminal tail (CTT, residues 326–333) that is not
present in DFS70/LEDGFp75 (Fig. 2a). These variants
localize to different nuclear regions and appear to play
opposing roles when ectopically overexpressed, with
DFS70/LEDGFp75 acting as a stress survival protein and
p52 as a pro-apoptotic protein [33, 35]. P52 has been
particularly implicated in splicing regulation through
binding to trimethylated histone H3K36me3 and splicing
factor SRSF1, and in the regulation of neurite growth in rat
retinal ganglion cells [36–39].
Structural and functional domains
The N-terminal region shared by DFS70/LEDGFp75 and
p52 contains a PWWP domain (Fig. 2a), defined by a
Table 1 Key milestones in the history of the DFS70/LEDGFp75 autoantigen-autoantibody system
Year Milestone References
1994 Discovery of serum autoantibodies recognizing the nuclear DFS-IIF pattern in patients with interstitial
cystitis
[4]
1997 Partial cDNA sequence encoding the autoepitope region of the DFS70 autoantigen deposited in GenBank
under accession number U94319
[3]
1998 Discovery of transcription co-activator p75, later known to be identical to DFS70 and LEDGFp75 [13]
1999 Discovery of LEDGFp75 using autoantibodies from a cataract patient [14]
2000 Characterization of DFS70 using autoantibodies from patients with atopic dermatitis and other
conditions, and initial observation that these autoantibodies are present at low frequencies in SARD
patients
[3]
2001–2002 Demonstration that DFS70/LEDGFp75 is cleaved during cell death into fragments that are recognized by
autoantibodies
[32, 98]
2003–2004 Discovery of DFS70/LEDGFp75 as a key cellular co-factor of HIV-1 integration [17–20]
2004 Initial observation that anti-DFS70/LEDGFp75 autoantibodies are present in apparently healthy
individuals
[125]
2004 Identification of a major B cell autoepitope in the carboxy-terminal region of DFS70/LEDGFp75 [62]
2005 Identification of DFS70/LEDGFp75 as a tumor associated autoantigen [99]
2005 Demonstration that anti-DFS70/LEDGFp75 autoantibodies are a very common occurrence in human sera
screened for ANAs by HEp-2 IIF in a clinical laboratory and can be detected in a wide array of
immunological conditions
[7]
2008 Observation that patients producing anti-DFS70/LEDGFp75 autoantibodies as the only serum ANA
pattern are rarely diagnosed with SARD
[28]
2011–2012 Description of anti-DFS70/LEDGFp75 autoantibodies as a potential exclusion biomarker for SARD [26, 107]
2012 Development of a highly specific ANA test based on immunoadsorption of anti-DFS70/LEDGFp75
autoantibodies
[5]
2012 Introduction of a new algorithm for ANA testing that considers anti-DFS70/LEDGFp75 autoantibodies [6]
2013 First commercially available diagnostic test (Inova Diagnostics) for the detection of anti-DFS70/
LEDGFp75 antibodies
N/A
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proline-tryptophan-tryptophan-proline motif (residues
19–22). PWWP domains are highly conserved in members
of the hepatoma-derived growth factor (HDGF) family and
in several DNA-binding proteins and have been implicated
in chromatin binding, HIV-integration, protein–protein
interactions, transcription, and DNA methylation [40–43].
This domain facilitates the dynamic scanning and hopping
of DFS70/LEDGFp75 along the chromatin, and the locking
into chromatin of interacting proteins that are bound to its
C-terminus [44]. Binding of this domain to chromatin is
facilitated by its interaction with H3K36me3 [45]. Other
sequences such as positively charged regions, a nuclear
localization signal and AT-hook motifs (Fig. 2a), also con-
tribute to DFS70/LEDGFp75 binding to chromatin, partic-
ularly to H3K4me3 at active transcription sites [46–50].
Both the N- and C-terminal regions of DFS70/
LEDGFp75 contribute to its transcription and stress sur-
vival functions by engaging in interactions with chromatin-
binding proteins, or by binding to promoters of specific
stress genes [33, 42, 48, 51–56]. Chromosomal transloca-
tions in leukemia produce a NUP98-LEDGFp75 fusion
protein lacking the N-terminal region of DFS70/
LEDGFp75, resulting in a PWWP-deficient protein with
deregulated transcription functions [56–60]. The C-termi-
nal region of DFS70/LEDGFp75 (residues 325–530),
absent in p52, contains two helix-turn-helix domains
(residues 421–442 and 471–492) that are capable of bind-
ing heat shock elements within promoter regions of stress
genes [48]. The C-terminal region of DFS70/LEDGFp75
also encompasses the HIV integrase-binding domain (IBD,
Human anti-DFS70/LEDGFp75
Rabbit anti-LEDGFp75 (Bethyl)
DNA staining with DAPI














Fig. 1 Characteristic features of human autoantibodies to DFS70/
LEDGFp75. a Staining pattern produced by human and rabbit
autoantibodies to DFS70/LEDGFp75 in HEp-2 slides visualized by
IIF microscopy using FITC-labeled secondary antibodies. Yellow
arrows point to bright staining in condensed metaphase
chromosomes. b Confocal microscopy images showing reactivity of
a human DFS70/LEDGFp75 autoantibody in U2OS cells. c Im-
munoblot showing reactivity of representative DFS-IIF-positive
patient sera against a single band of approximately 75 kD in PC3
cell lysates (Color figure online)
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residues 347–429), which is recognized by the HIV-1
integrase (HIV-IN) [17–20, 61].
Autoepitope mapping in DFS70/LEDGFp75
The C-terminus of DFS70/LEDGFp75 contains the
autoepitope (aa 347–429) recognized by the autoantibodies
[62], which explains why these consistently recognize a
single band of 70–75 kD and not the p52 variant in
immunoblots of cell lysates (Fig. 1b). Intriguingly, this
immunogenic region is essentially the same region com-
prised by the IBD [18, 61, 63] and shares significant
homology with HRP-2 (HDGF-related protein 2), a mem-
ber of the HDGF protein family that can also interact with
HIV-IN [64].
The biological significance of these coincidental find-
ings is not presently clear and raises interesting questions.
Why would an epitope region targeted by autoantibodies
correspond to the exact same region specifically recognized
by the HIV-IN? What structural or functional elements
within this region make it attractive for targeting by both
the immune system and the HIV-1 virus? While at the
present time we lack sufficient information to answer these
questions, it is evident that the autoepitope/IBD region has
intrinsically important cellular functions. These include, in
addition to HIV-IN binding, serving as a hub for protein–
protein interactions in the chromatin, regulation of gene
expression, and stress survival activity. It should be noted
that DFS70/LEDGFp75 is predicted to be a highly disor-
dered protein, a feature of proteins that have multiple
interacting partners [61]. One could speculate that the
largely disordered nature of DFS70/LEDGFp75 and the
promiscuity of its autoepitope/IBD domain in interacting
with multiple proteins (both self and non-self), may influ-
ence its proteolytic processing and presentation to the
immune system. This could contribute to enhanced
immunogenicity under pro-inflammatory conditions, lead-
ing to autoantibody generation in susceptible individuals.
The autoimmune targeting of the IBD is consistent with the
notion that autoantibody-defined epitopes typically com-
prise highly conserved, conformational, and functional
domains [1, 2].
Cellular and tissue expression of DFS70/
LEDGFp75
DFS70/LEDGFp75 exhibits transcript expression in vari-
ous human tissues [14]. Its expression may be differentia-
tion-related, as suggested by the higher mRNA and protein
levels in fetal brain compared to adult brain, and its loss
from nuclei of differentiating LECs [65, 66]. DFS70/
LEDGFp75 is also expressed in LECs, keratinocytes,
fibroblasts, and most laboratory transformed cell lines, with
elevated levels in cancer cells [14, 15, 31–34].
Cellular functions of DFS70/LEDGFp75
Protection against environmental stress
Compelling evidence supports a cellular protective func-
tion for DFS70/LEDGFp75 against environmental factors
that induce cellular stress, such as ultraviolet B (UVB)
irradiation, hydrogen peroxide, alcohol, hyperthermia,
nutrient deprivation, and certain chemotherapeutic drugs
[14, 31, 32, 34, 51, 67–73]. These stressors can lead to
increased oxidative stress, which induces upregulation and
activation of DFS70/LEDGFp75 [73].
DFS70/LEDGFp75 is presumed to promote cellular
protection against environmental stressors by transcrip-
tionally activating stress, antioxidant, and other protective
genes [51, 74–82]. However, to date only a few target
genes of DFS70/LEDGFp75 have been identified and
validated (Table 2). While global gene profiling studies on
cells stably depleted of DFS70/LEDGFp75 failed to reveal
a specific genetic pathway regulated by this protein [12],
studies using pathway-specific gene arrays showed that
ectopic overexpression or transient depletion of this protein
in cancer cells under stress led to significant changes in the
expression of certain stress and antioxidant genes [82].
These findings suggested that DFS70/LEDGFp75 con-
tributes to the regulation of stress gene expression mainly
















Fig. 2 Main splicing variants of DFS70/LEDGFp75. a Depiction of
the two major splice variants of DFS70/LEDGFp75, namely p75 and
p52, with their domains and motifs. b Immunoblot showing the
reactivity of a commercial monoclonal antibody (BD Biosciences)
directed against the N-terminal region of DFS70/LEDGFp75 that
recognizes both splice variants in a panel of cancer cell lines
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DFS70/LEDGFp75 interactome
Both the PWWP domain and the C-terminal IBD region of
DFS70/LEDGFp75 interact with various chromatin-asso-
ciated proteins, likely facilitating DFS70/LEDGFp75
function in stress gene expression regulation. Interactors of
the IBD in addition to HIV-IN include the pogo transpos-
able element PogZ, the c-Myc interacting protein JPO2, the
Cdc7-activator of S-phase kinase (ASK), and the leukemia-
associated transcription complex Menin-MLL (mixed lin-
eage leukemia) [52–56, 83]. The PWWP domain has been
implicated in binding to the methylation-associated protein
MeCP2, transcription coactivator TOX4, and splicing
cofactor NOVA1 [42, 84]. DFS70/LEDGFp75 also par-
ticipates in the recruitment of polycomb group protein
Bmi1 and co-repressor Ctbp1 to MLL complexes in HOX
gene promoters [85].
Cell death and survival decisions
Various groups have reported that depletion or functional
inactivation of DFS70/LEDGFp75 leads to decreased cell
survival [15, 32, 33, 57, 72, 86, 87]. However, these results
are controversial because others have reported that this
protein is not essential for cell survival based on observa-
tions that cell clones with stable depletion of the protein
can survive in culture [88, 89]. In addition, a PSIP1/
LEDGF-/- knockout mouse model revealed that disruption
of this gene is not intrinsically lethal to mice [16]. While
these conflicting observations are likely to be cell type- and
context-dependent, it is possible that selected cell clones
with stable depletion of DFS70/LEDGFp75 may have
developed compensatory mechanisms to survive in the
absence of this protein. This is supported by the observa-
tion that prostate cancer (PCa) cell clones with stable
Table 2 List of candidate target genes of DFS70/LEDGFp75
Gene Description Method of discovery Validation References
ADH and Alcohol dehydrogenase and EMSA Transcription reporter assays [78]
ALDH aldehyde dehydrogenase















Homeobox genes Gene microarray, RNAi qPCR [16, 56,
85]




IL-6 Interleukin 6 (interferon, beta 2) qPCR, immunoblotting,
overexpression
RNAi [103, 104]










SOD3 Superoxide dismutase 3 qPCR Array, RNAi,
overexpression
qPCR [82]
TPO Thyroid peroxidase qPCR Array, RNAi,
overexpression
qPCR [82]





Small stress protein alpha basic crystallin DNase I footprinting Transcription reporter assays, RT-
PCR, EMSA, RNAi
[51, 79]




qPCR, immunoblotting, RNAi [71]
ChIP chromatin immunoprecipitation, EMSA electrophoretic mobility shift assay, IHC immunohistochemistry, RNAi RNA interference, RT-PCR
reverse transcription polymerase chain reaction, qPCR quantitative, real-time PCR
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DFS70/LEDGFp75 depletion did not display significant
changes in stress gene expression when compared to
stressed cells with transient depletion [82].
The possibility that DFS70/LEDGFp75 is needed
mainly in the context of stress survival was suggested by
the observation that deletion mutants of the protein lacking
portions of its N- and C-terminal domains did not show any
effects on cell death or survival when stably overexpressed
in cancer cells growing under normal conditions [32].
However, unlike the full-length protein, these mutants were
unable to support cell survival under starvation stress [32].
Transactivation of protective genes by DFS70/
LEDGFp75 under cellular stress is likely to contribute to
preservation of the structural integrity of critical organelles
that are highly susceptible to oxidative damage and that
regulate cell death and survival. Consistent with this,
DFS70/LEDGFp75 was shown to protect cancer cells
against antitumor drugs that induce lysosomal membrane
permeabilization (LMP) and cell death [34, 72]. PCa cell
lines selected in culture for natural resistance to docetaxel,
an antitumor drug that induces LMP and is antagonized by
DFS70/LEDGFp75, express high levels of this autoantigen,
consistent with the possibility that chemotherapeutic stress
induces its expression [31, 34, 82].
DFS70/LEDGFp75 has also been implicated in cellular
protection against oxidative DNA damage. It enhanced the
survival of retinal pigment epithelial cells challenged by
oxidative stress or UVB irradiation [70], a survival effect
associated with DFS70/LEDGFp75-mediated protection of
DNA from single-strand breakage and upregulation of
Hsp27. This is consistent with studies showing that DFS70/
LEDGFp75 promotes repair of DNA double-strand breaks
through the homologous recombination repair pathway
[90].
Regulation of DFS70/LEDGFp75 expression
and function
Transcriptional regulation
Increased cellular expression of the Sp1 transcription factor
leads to upregulation of DFS70/LEDGFp75 via TATA-less
promoter activation, while its inhibition represses this
upregulation [91, 92]. However, during LEC exposure to
UVB, a histone deacetylase/histone methylase (HDAC1/
SUV39H1) complex is recruited to Sp1 responsive ele-
ments in the DFS70/LEDGFp75 gene promoter, leading to
attenuation of Sp1 binding, repression of DFS70/
LEDGFp75 expression, and increased cellular oxidative
stress and death [93]. These results suggest that certain
stressors may either upregulate or repress DFS70/
LEDGFp75 depending on context.
Transforming growth factor beta 1 (TGF-b1) is also
known to downregulate DFS70/LEDGFp75 in LECs by
binding to its promoter region [77]. This is consistent with
the observations that a Prdx6-/- knockout mouse cell line
displayed increased TGF-b1 levels with reduced DFS70/
LEDGFp75 [94] and that an inverse expression relationship
between these genes exists in diabetic and galactosemic
cataractous rat lenses [95].
There is also evidence that DFS70/LEDGFp75 is regu-
lated at the transcriptional level by micro-RNAs (miR-
NAs). Macrophages stimulated with lipopolysaccharide
induced miR-155, concomitant with downregulation of
DFS70/LEDGFp75, and ectopic expression of this miRNA
reduced DFS70/LEDGFp75 expression at the transcrip-
tional level [96]. Another miRNA, miR-135b, also down-
regulated DFS70/LEDGFp75 both in human cell lines and
in murine vestibular sensory epithelia of the inner ear, and
it was suggested that this downregulation could influence
inner ear cell survival, protection against stress, develop-
ment, and differentiation [97].
Functional regulation by repression of transcription
function
Differential expression of DFS70/LEDGFp75 and its short
splice variant p52 was observed in a panel of cancer cell
lines, with DFS70/LEDGFp75 expressed at higher levels
[32–34]. Interestingly, ectopic overexpression of p52
induced decreased cell survival via caspase-dependent
apoptosis associated with DFS70/LEDGFp75 cleavage
[33]. During apoptosis, caspase-3 cleaves DFS70/
LEDGFp75 to generate several fragments [32, 33, 98, 99].
As shown in Fig. 3, treatment of Jurkat T cells for 6 h with
staurosporine (STS) induces the classical apoptosis mor-
phology (Fig. 3a), which is associated with cleavage of
DFS70/LEDGFp75 into fragments of 68, 65, and 58 kD
that are recognized by the autoantibodies in immunoblots
of whole-cell lysates (Fig. 3b). Consistent with this,
autoantibody recognition of DFS70/LEDGFp75 in apop-
totic blebs can be detected by IIF microscopy (Fig. 3c).
These fragments are produced by caspase-3-mediated
sequential cleavage of the protein at specific aspartic acid
residues located in the N-terminal PWWP domain and the
C-terminal region (Fig. 3d). This apoptotic cleavage
impairs DFS70/LEDGFp75’s stress survival activity and
generates fragments that enhance cell death under stress
[32]. An interesting observation was that during apoptosis,
p52 is also cleaved by caspase-3 to generate a p38 fragment
that antagonizes the transcriptional function of DFS70/
LEDGFp75 [33].
The pro-survival protein Bcl-2 was also shown to
attenuate DFS70/LEDGFp75 stress survival and tran-
scriptional activities in LECs by interfering with its binding
Clin Exp Med (2016) 16:273–293 279
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to the promoter region of the gene encoding aB crystallin
[100]. It is plausible that these pro-survival proteins
antagonize different cell death pathways, prompting cells
to tightly regulate their expression.
Functional regulation by sumoylation
DFS70/LEDGFp75 is post-translationally sumoylated at
different sites in its N-terminal and C-terminal regions
[101]. While sumoylation does not affect its cellular
localization and chromatin-binding ability, it provides a
mechanism to regulate its transcriptional activity, as
suggested by the observation that mutations of DFS70/
LEDGFp75 sumoylated sites extended its half-life and
increased its transcriptional activity [101]. Consistent
with these observations, LECs expressing sumoylation-
deficient DFS70/LEDGFp75 displayed increased tran-
scriptional and cellular survival activities compared to
wild-type protein [102]. These results suggested that




Overexpression of DFS70/LEDGFp75 has been shown to
induce the IL-6/STAT3 signaling pathway in HaCaT skin
cells, whereas its knockdown reduced IL-6 levels [103,
104]. Interestingly, the intracellular localization of both
DFS70/LEDGFp75 and phosphorylated STAT3 in HaCaT
cells appears to be regulated by Ran-binding proteins,
which suggested that a similar mechanism may be oper-
ating in psoriatic keratinocytes [105]. Additional evidence
supporting a link between DFS70/LEDGFp75 and STAT3
came from studies demonstrating that switching the
expression of STAT3 to STAT3b, its dominant negative
truncated variant, in cancer cells led to DFS70/LEDGFp75
repression [106]. These observations suggested that
DFS70/LEDGFp75 is activated by STAT3 in an auto-
crine/paracrine loop and raised the interesting possibility
that a regulatory crosstalk between this autoantigen and the
IL-6/STAT3 pathway may contribute to inflammatory
processes [106]. Consistent with a link between DFS70/
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Fig. 3 Apoptotic cleavage of DFS70/LEDGFp75. a Jurkat T cells
undergoing apoptosis after exposure to staurosporine (STS). b Im-
munoblot showing cleavage of DFS70/LEDGFp75 into various
fragments during STS-induced apoptosis in Jurkat cells. These
fragments were detected with human autoantibodies to DFS70/
LEDGFp75. c Confocal microscopic image of DFS70/LEDGFp75
autoantibody staining in U2OS cells undergoing apoptosis (yellow
arrow depicts apoptotic blebs retaining DFS70/LEDGFp75 staining).
d Diagram illustrating caspase-mediated sequential cleavage of
DFS70/LEDGFp75 (Color figure online)
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LEDGFp75 activation and inflammation, Takeichi et al.
[104] also observed that DFS70/LEDGFp75 stimulated
release of the cytokines TNF and IL-8 from keratinocytes.
Interestingly, treatment of LECs with sublethal doses of
TNF resulted in induction of oxidative stress and elevated
expression of DFS70/LEDGFp75, which in turn transacti-
vated the protective protein gamma glutamylcysteine syn-
thetase [71].
Clinical associations of anti-DFS70/LEDGFp75
autoantibodies
During the past 15 years, several groups have documented
the presence of autoantibodies to DFS70/LEDGFp75 in
apparently healthy individuals (HI) and in a variety of
conditions associated with inflammation and oxidative
stress (Table 3). Below, we briefly discuss these clinical
associations and their implications.
Autoantibodies to DFS70/LEDGFp75 in IC
Ochs et al. [3, 4] investigated the presence of ANAs in sera
of IC patients, especially noting whether or not their
specificities were unique or similar to SARD-related
ANAs. Among the ANA patterns observed in sera from 96
patients, there was a predominance of the nuclear DFS-IIF
pattern (69 % of all ANA-positive patients and 9 % of the
total cohort). Immunoblotting analysis confirmed that these
DFS-positive sera contained autoantibodies to DFS70/
LEDGFp75 [3]. A later study found only a 5 % frequency
of these antibodies in IC patients when detected by the
Quanta Flash DFS70 chemiluminescence assay (DFS70-
CIA) [107].
Anti-DFS70/LEDGFp75 autoantibodies in atopic
and skin disorders
Ochs et al. [3] also observed that sera from 28 to 16 %
patients with atopic dermatitis (AD) and asthma, respec-
tively, produced the DFS-IIF pattern. Immunoblotting with
recombinant DFS70/LEDGFp75 confirmed the presence of
IgG and IgE autoantibodies to this protein. Other disease
cohorts tested, including SARD, revealed low frequency
(\5 %) of these antibodies, suggesting that this autoanti-
body-autoantigen system is not associated with SARD [3].
The presence of anti-DFS70/LEDGFp75 autoantibodies
in AD was confirmed by the observation that some AD
patients producing these autoantibodies also had cataracts
[108]. In addition, these antibodies (both IgE and IgG4)
were detected at a prevalence of 15 % in AD patients, and
their presence correlated with elevated thymus and acti-
vation-regulated chemokine, which is associated with
increased AD severity [23]. Immunohistochemical (IHC)
analysis showed that DFS70/LEDGFp75 was present in
epidermal cells and infiltrating monocytes in the skin of
AD patients, suggesting that DFS70/LEDGFp75 upregu-
lation or release from damaged tissue or invading cells may
trigger autoantibody responses [23]. It should be noted,
however, that the elevated prevalence of these autoanti-
bodies in AD could not be confirmed using DFS70-CIA,
highlighting the inter-laboratory and inter-diagnostic plat-
form differences in the detection of these autoantibodies
[107]. Differences in cohort collection and composition
(age, gender, race) may also explain these discrepancies.
DFS70/LEDGFp75 is predominantly located in the
nucleus of basal epidermal cells and then translocates into
the cytoplasm during differentiation, where it accumulates
in the granular layer of keratohyalin granules, which are
important for proper keratinocyte apoptosis [109]. It was
hypothesized that anti-DFS70/LEDGFp75 autoantibodies
may affect its pro-survival function and contribute to the
development of skin disease [109]. However, this would be
plausible only in the context of extracellular release of
DFS70/LEDGFp75.
Takeichi et al. [103] observed that DFS70/LEDGFp75, in
addition to inducing the IL-6/STAT-3 pathway in cultured
skin cells, localized to the nucleus of keratinocytes in psori-
atic lesions, which suggested a pivotal role for this autoanti-
gen in protecting psoriatic keratinocytes under a stressful
microenvironment. They suggested that downregulation of
DFS70/LEDGFp75 may mitigate psoriasis symptoms by
attenuating keratinocyte proliferation in psoriatic lesions.
Anti-DFS70/LEDGFp75 autoantibodies have also been
found in 19.8 % of patients with alopecia areata (AA), an
inflammatory skin condition that has autoimmune under-
pinnings, compared to 7.6 % of HI controls [21]. IHC
analysis revealed that DFS70/LEDGFp75 localized to the
outer root sheath cells of the hair follicle, the area that is
targeted by the immune response in AA patients, suggest-
ing that anti-DFS70/LEDGFp75 antibodies may contribute
to AA pathophysiology [21].
Anti-DFS70/LEDGFp75 autoantibodies in eye
diseases
Anti-DFS70/LEDGFp75 antibodies have been detected in
diverse eye diseases [9, 22, 25, 110]. Ayaki et al. [108,
111] reported that these antibodies induce cytotoxicity in
LECs, suggesting a pathogenic role. They proposed that the
antibodies absorb extracellularly released DFS70/
LEDGFp75, preventing its re-entry into LECs where it acts
as a pro-survival factor. This is consistent with previous
observations that DFS70/LEDGFp75 is secreted by LECs
and that its absorption by autoantibodies added to the
culture medium reduced cell survival under stress [15].
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Table 3 Clinical associations of autoantibodies to DFS70/LEDGFp75 or sera presenting the dense fine speckled pattern
Category Reactivity (positive/total) Frequency (%) Detection methods References
Alopecia areata 22/111 20 HEp-2 IIF, WB, ELISA [21]
Arthralgia 16 of 81 DFS-positive sera 19.8 HEp-2 IIF [7]
2 of 34 DFS-positive sera 5 HEp-2 IIF, CIA [130]
Asthma 8/50 16 HEp-2 IIF, WB [3]
1/25 4 CIA [107]
Atopic dermatitis 19/64 29.6 HEp-2 IIF, WB, [3]
15/21 (children) 71.4 ELISA [108]
23/61 37.7 ELISA [23]
0/16 0 CIA [107]
Atopic dermatitis with cataract 8/8 100 ELISA [108]
Atypical retinal degeneration ND (3 case studies) NA WB, SEREX [110]
Autoimmune fatigue syndrome 226 cases, reactivity not clearly stated *40 ELISA, WB [115]
Autoimmune thyroiditis 13 of 81 DFS-positive sera 16 HEp-2 IIF [7]
4/67 6 CIA [107]
Behcet’s disease 11/32 34.4 ELISA [25]
Blood bank donors 35/650 5.4 ELISA [108]
Cancer (various types) 6/334 1.8 HEp-2 IIF [22]
0/40 0 HEp-2 IIF, CIA [107]
3 of 81 DFS-positive sera 3.7 HEP-2 IIF [7]
Clinical referrals or routine 53/3263 1.6 HEp-2 IIF, ELISA, CIA [107]
ANA testing 5,081 of 13,641 ANA-positive sera 37 HEp-2 IIF [7]
172/21,516 0.8 HEp-2 IIF [22]
101/2,654 3.8 HEp-2 IIF [128]
101 of 352 ANA-positive sera 28.7 HEp-2 IIF [128]
57/2,788 2 HEp-2 IIF [129]
57 of 790 ANA-positive sera 7.2 HEp-2 IIF [129]
Chronic fatigue syndrome 2/60 3.3 HEp-2 IIF, WB [3]
2 of 81 DFS-positive sera 2.5 HEp-2 IIF [7]
18 of 21 ANA-positive children 86 HEp-2 IIF, WB [116]
36 cases, reactivity not clearly stated *40 ELISA, WB [115]
Diverse dermatological conditions 39 of 115 ANA-positive sera 34 HEp-2 IIF [128]
Dermatomyositis/polymyositis 4/80 5 HEp-2 IIF, WB [28]
7/116 6 HEp-2 IIF, ELISA [123]
Diffuse pain 21 of 81 DFS-positive sera 26 HEp-2 IIF [7]
Fibromyalgia 3 of 81 DFS-positive sera 3.7 HEp-2 IIF [7]
3 of 34 DFS-positive sera 9 HEp-2 IIF, CIA [130]
1 of 15 ANA-positive children 4.8 HEp-2 IIF, WB [116]
Graves disease 1/60 1.7 CIA [107]
Gynecologic syndromes 2 of 81 DFS-positive sera 2.5 HEp-2 IIF [7]
Healthy donors 0/39 0 HEp-2 IIF, WB [3]
8/37 21.6 ELISA [25]
64/597 11 HEp-2 IIF, WB, ELISA [125]
8/105 7.6 WB, ELISA [21]
11/124 8.9 HEp-2 IIF, ELISA, [107]
39/918 4.2 CIA HEp-2 IIF [26]
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Table 3 continued
Category Reactivity (positive/total) Frequency (%) Detection methods References
39 of 118 ANA-positive sera 33.1 HEp-2 IIF [26]
16 of 34 DFS-positive sera 47 HEp-2 IIF, CIA [130]
Infectious diseases 0/20 0 CIA [107]
6 of 81 DFS-positive sera 7.4 HEp-2 IIF [7]
Inflammatory bowel disease 0/34 0 CIA [107]
Interstitial cystitis 9/103 8.7 HEp-2 IIF, WB [3]
2/40 5 CIA [107]
Multiple sclerosis 0/10 0 CIA [107]
1 of 81 DFS-positive sera 1.2 HEp-2 IIF [7]
2 of 172 DFS-positive sera 1.2 HEp-2 IIF [22]
Prostate cancer (PCa) 46/206 22.3 HEp-2 IIF, ELISA, WB [99]
Matched controls for PCa 9/164 5.4 ELISA [99]
Rheumatoid arthritis 0/30 0 HEp-2 IIF, WB, [3]
0/40 0 HEp-2 IIF, WB, ELISA [125]
16 of 172 DFS-positive sera 9.3 HEp-2 IIF [22]
1/39 2.6 CIA [107]
2 of 81 DFS-positive sera 2.4 HEp-2 IIF [7]
0/13 0 HEp-2 IIF, WB [28]
11/65 16.9 HEp-2 IIF [128]
2/13 15.3 HEp-2 IIF [128]
2 of 34 DFS-positive sera 5.8 HEp-2 IIF, CIA [130]
Sarcoidosis 4/16 25 ELISA [25]
Scleroderma/systemic sclerosis 1/40 2.5 HEp-2 IIF, WB [3]
0/50 0 HEp-2 IIF, WB, ELISA [125]
2 of 172 DFS-positive sera 1.2 HEp-2 IIF [22]
0/29 0 CIA [107]
1/164 0.006 HEp-2 IIF, WB [28]
1 of 91 DFS-positive sera 1.1 CIA [24]
Sjo¨gren’s syndrome 2/29 6.9 HEp-2 IIF, WB [3]
2/30 6.7 HEp-2 IIF, WB, ELISA [125]
4 of 172 DFS-positive sera 2.3 HEp-2 IIF [22]
0/7 0 CIA [107]
8/71 11.3 HEp-2 IIF, WB [28]
2 of 34 DFS-positive sera 5.8 HEp-2 IIF, CIA [130]
Systemic lupus erythematosus 0/36 0 HEp-2 IIF, WB [3]
1/55 2 HEp-2 IIF, WB, ELISA [125]
5 of 172 DFS-positive sera 2.9 HEp-2 IIF [22]
7/251 2.8 CIA [107]
5 of 81 DFS-positive sera 6.2 HEp-2 IIF [7]
7/124 5.6 HEp-2 IIF, WB [28]
4 of 91 DFS-positive sera 4.3 CIA [24]
Sympathetic ophthalmia 5/7 71.4 ELISA [25]
Vogt–Koyanagi–Harada Syndrome 24/36 66.7 ELISA [25]
CIA Inova QuantaFlash chemiluminescence assay, DFS dense fine speckled, ELISA enzyme-linked immunosorbent assay, IIF indirect
immunofluorescence microscopy, WB Western blotting, IP immunoprecipitation, ND not determined, NA not available
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Bizzaro et al. [22] reported that over 20 % of human
sera showing the DFS-IIF pattern in HEp-2 cells also
reacted strongly against reticular fibers of the lens and the
corneal epithelium. These DFS-positive sera, however,
produced different distribution patterns, suggesting the
presence of companion autoantibodies targeting interacting
ligands of DFS70/LEDGFp75. These authors noted that it
is not easy to recognize the DFS pattern by IIF microscopy
and therefore this method should not be used alone as the
preferred technology to measure anti-DFS70/LEDGFp75
antibodies [22, 112].
Autoantibodies to DFS70/LEDGFp75 have also been
reported in Vogt–Koyanagi–Harada (VKH) disease, an
inflammatory disorder affecting multiple organs containing
melanocytes, including uvea, skin, central nervous system,
and inner ears [25]. Their presence was confirmed by
ELISA in 67 % of VKH patients and in other patients with
panuveitis, including sympathetic opthalmia, Behcet’s
disease, and sarcoidosis (Table 3). Notably, these anti-
bodies were also detected in 22 % of HI, which suggested
the influence of background reactivity or selection of a low
cutoff value in the ELISA.
Chin et al. [110] identified high-titer anti-DFS70/
LEDGFp75 autoantibodies in three of six patients with
atypical retinal degeneration. IHC studies using these
autoantibodies demonstrated the presence of DFS70/
LEDGFp75 in nuclei from murine retinal ganglion and
pigment epithelial cells [110]. Consistent with this, DFS70/
LEDGFp75 protected retinal pigment epithelial cells from
nuclear damage induced by rhodopsin, a protein that forms
nuclear aggregates causing cell death and retinal degener-
ation [113, 114].
Anti-DFS70/LEDGFp75 autoantibodies in CFS
A low frequency of anti-DFS70/LEDGFp75 autoantibodies
(3.3 %) was reported in adult patients with CFS [3].
However, other studies reported an elevated presence of
these autoantibodies in children with CFS but not in chil-
dren with fibromyalgia (FM) [115, 116]. These findings are
intriguing and should be confirmed in large cohorts of
adults and children with CFS and FM diagnoses. Children
with other non-autoimmune conditions may also produce
these autoantibodies, as highlighted by a recent case report
of an 8-year-old patient with respiratory distress who pre-
sented high-titer anti-DFS70/LEDGFp75 autoantibodies
with no evidence of SARD [117]. The authors concluded
that these antibodies were a useful biomarker to rule out
suspected autoimmune disease in that particular case [117].
It should be noted, however, that ANA prevalence, speci-
ficity, and titers may change during puberty, which could
explain the observed differences in autoantibody frequen-
cies between children and adults [118].
Anti-DFS70/LEDGFp75 autoantibodies in cancer
During a screening of sera from patients with PCa for the
presence of autoantibodies to tumor associated antigens,
Daniels et al. [99] observed that the DFS-IIF pattern was
predominant in sera from PCa patients compared to mat-
ched controls. Immunoblotting analysis of these DFS-IIF-
positive sera, using PCa cell lysates as substrates, revealed
that the majority reacted with a 70-kD protein band, and
ELISA showed that 18.4 % of PCa sera reacted with this
protein, compared to 5.5 % of controls. Overall, 22.3 % of
the PCa sera reacted with DFS70/LEDGFp75 either by
ELISA or immunoblotting, compared to 6.7 % of matched
controls. Interestingly, the authors observed an incomplete
correlation in the detection of these antibodies between the
different immunoassays, which was attributed to differ-
ences in sensitivity and antigen conformation in the indi-
vidual assays [99]. More recently, other groups have
independently confirmed the presence of DFS70/
LEDGFp75 autoantibodies in PCa sera [119–121]. These
findings led to the hypothesis that DFS70/LEDGFp75
could be aberrantly expressed and functionally hyperactive
in PCa and perhaps other human cancers [99]. Numerous
studies have confirmed this hypothesis by showing altered
DFS70/LEDGFp75 expression and function in various
human cancer cell and tumor types, linking it to tumor
aggressive properties [31, 34, 56–60, 72, 80–82, 86, 87, 90,
99, 122].
It should be noted, however, that other studies have
reported low frequency of autoantibodies to DFS70/
LEDGFp75 in cancer patients [22, 107]. It is not clear
whether autoantibodies to DFS70/LEDGFp75 are more
prevalent in PCa patients than in patients with other can-
cers. Therefore, it would be important to determine the
frequency of these autoantibodies, using several detection
platforms, in large cohorts of ethnically diverse patients
with different cancer types as well as individuals at high
risk of developing cancer.
Low frequency of anti-DFS70/LEDGFp75
autoantibodies in SARD
The initial study on the clinical significance of these
autoantibodies revealed a relatively low frequency (2–4 %)
of these antibodies in patients with SARD [3]. This
observation was later reproduced in more comprehensive
studies performed by several other groups. For instance,
Dellavance et al. [7] reported that 30 % of ANA-positive
sera in a cohort of over 13,000 patients presented the DFS-
IIF pattern, with IgG titers ranging from 1:80 to over 1:640.
This was by far the overwhelming type of ANA-IIF pattern
detected in this large unbiased sample cohort. Clinical
information obtained for 81 of the DFS-IIF-positive serum
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donors indicated a diverse spectrum of disease conditions
that included organ-based autoimmune diseases and
inflammatory conditions. A key conclusion of this study
was that anti-DFS70/LEDGFp75 autoantibodies are a rel-
atively common finding among ANA-positive individuals
with no evidence of SARD [7].
Muro and colleagues examined 500 SARD sera for the
presence of anti-DFS70/LEDGFp75 antibodies, as well as
for SARD-associated marker autoantibodies [28]. They
found low frequencies of these autoantibodies and
observed that 86 % of the SARD patients positive for anti-
DFS70/LEDGFp75 autoantibodies also had at least one
SARD-marker autoantibody. These authors concluded that
patients with SARD producing anti-DFS70/LEDGFp75
antibodies as the only serum ANA-IIF pattern are rare and
that such antibodies could be used as exclusion biomarkers
of SARD in ANA-positive individuals.
Low prevalence (6.4 %) of these antibodies, detected by
ELISA and immunoblotting, were also reported in a cohort
of 103 Japanese patients with dermatomyositis (DM) [123].
Most patients producing these antibodies also produced
DM-specific autoantibodies, including antibodies to
MDA5, which are used as serological markers for aggres-
sive disease, particularly complications with interstitial
lung disease (ILD) [123, 124]. An interesting observation
was that three DM-ILD patients producing both anti-
DFS70/LEDGFp75 and anti-MDA5 antibodies who went
into remission after therapy had decreased levels of anti-
MDA5 autoantibodies concomitant with increased levels of
anti-DFS70/LEDGFp75 antibodies [123]. However, a
fourth patient with DM-ILD who produced both antibodies
and succumbed to the disease showed unchanged levels of
anti-MDA5 autoantibodies concomitant with decreased
levels of anti-DFS70/LEDGFp75 antibodies. These obser-
vations raised the intriguing hypothesis, which needs to be
further investigated in a larger patient cohort, that anti-
DFS70/LEDGFp75 antibodies may serve a protective role
[123]. However, it cannot be ruled out that these autoan-
tibodies might be acting as sensors of DFS70/LEDGFp75
upregulation in response to the systemic stress produced by
therapy in the surviving patients. To explore this possi-
bility, it would be important to compare the circulating
levels or diseased tissue expression of DFS70/LEDGFp75
in large cohorts of therapy-responding versus non-re-
sponding DM-ILD patients producing these antibodies.
Anti-DFS70/LEDGFp75 autoantibodies in healthy
individuals
Watanabe et al. [125] screened sera from 597 self-reported
healthy hospital workers for the presence of ANAs and
observed that 54 % of all ANA-positive individuals had
anti-DFS70/LEDGFp75 antibodies. This led to the
speculation that these antibodies may be naturally occur-
ring in both apparently HI and diseased individuals. It
should be cautioned, however, that hospital personnel tends
to present higher ANA levels than blood donors or relatives
of SARD patients [126].
Later studies confirmed that anti-DFS70/LEDGFp75
antibodies are more prevalent in apparently HI than in
patients with SARD. For instance, Mariz et al. [26]
screened 918 HI (negative history of SARD, infections, and
inflammatory conditions) and 153 SARD patients for the
prevalence of ANAs, as detected by HEp-2 IIF. The DFS-
IIF and the nuclear fine speckled (unrelated to DFS70/
LEDGFp75) patterns were the most frequent (approxi-
mately 33 and 46 %, respectively) in ANA-positive HI.
Another similar HEp-2-IIF pattern characterized by fine
grainy nuclear staining with staining of metaphase chro-
mosomes, designated as quasi-homogeneous pattern, was
observed in 4 % of the ANA-positive HI [26]. Confirma-
tion that the DFS-IIF pattern was associated with anti-
bodies to DFS70/LEDGFp75 was obtained by
immunoblotting, whereas sera positive for the nuclear fine
speckled and quasi-homogeneous patterns did not react
with the protein. Interestingly, antibody titers reached
1:640 and 1:1280 in 50 % of the DFS-IIF-positive sera,
with titers[1:5,120 in three individuals. Follow-up studies
revealed that the presence and titers of anti-DFS70/
LEDGFp75 antibodies were stable over the years and that
the positive HI did not subsequently develop SARD or any
evident disease [26]. This is in contrast to the known pre-
dictive value of disease marker ANAs for SARD diagnosis
[127]. Mariz et al. [26] pointed to the difficulty of distin-
guishing the nuclear fine speckled and the quasi-homoge-
neous nuclear patterns from the DFS-IIF pattern in HEp-2
substrates, even by trained laboratory personnel, and rec-
ommended expanding efforts to address the reproducibility
of ANA-HEp-2 test interpretations among different experts
and commercial brands.
Mahler et al. [107] reported a prevalence of anti-DFS70/
LEDGFp75 antibodies of 8.9 % (determined by DFS70-
CIA) in a cohort of 124 serum samples from clinically
defined HI with no history of SARD. This prevalence was
significantly higher than in patients with SARD and non-
SARD diseases, which exhibited prevalences below 6 %.
These authors noted that in an SLE cohort there were no
clinical differences between the few patients with anti-
DFS70/LEDGFp75 antibodies and the patients without
these antibodies, suggesting that the antibodies are not
protective and do not correlate with disease activity. They
also observed that in the SLE cohort all but one of the
patients with anti-DFS70/LEDGFp75 antibodies also had
other classical SLE-associated autoantibodies [107]. These
findings reinforced the notion that anti-DFS70/LEDGFp75
antibodies are more prevalent in HI than in SARD patients.
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However, given that a small proportion (2–3 %) of SARD
patients in this and other studies also produced these
antibodies [3, 28], it cannot be asserted conclusively that
these antibodies are highly accurate biomarkers for SARD
exclusion, unless they are the only ANA specificity
detected in the sera.
Studies with large cohorts of well-defined SARD
patients are necessary to determine whether the presence of
anti-DFS70/LEDGFp75 autoantibodies in these patients is
coincidental or associated with a specific clinical pheno-
type or therapy. Along these lines, a novel immunoad-
sorption technology has been developed to increase the
specificity of the ANA-HEp-2 cell assay [5]. Using
recombinant DFS70/LEDGFp75 in the dilution buffer,
anti-DFS70/LEDGFp75 antibodies are prevented from
binding their target in HEp-2 cells [5, 6]. This then reveals
the clinically relevant IIF pattern in sera with concomitant
anti-DFS70/LEDGFp75 and other SARD-marker
autoantibodies.
Prevalence of anti-DFS70/LEDGFp75 antibodies
in routine ANA testing
Mahler et al. [107] screened 3,263 serum samples sub-
mitted for ANA testing for the presence of anti-DFS70/
LEDGFp75 autoantibodies and observed that 1.62 % pre-
sented the DFS-IIF pattern, which was confirmed to cor-
respond to anti-DFS70/LEDGFp75 autoantibodies when
evaluated by DFS70-specific ELISA and CIA. Bizzaro
et al. [22] also observed low frequency (0.8 %) of sera
displaying the DFS-IIF pattern in HEp-2 cells in 21,512
samples screened for ANA in the clinical laboratory. Two
additional studies also reported low frequencies (\4 %) of
this pattern in thousands of sera screened for ANAs [128,
129].
Miyara et al. [24] evaluated the clinical value of anti-
DFS70/LEDGFp75 autoantibodies in patients undergoing
routine ANA testing. Analysis of sera from 100 consecu-
tive patients with DFS-IIF pattern and 100 patients with
other patterns, using the ANA-HEp-2 test, DFS70 CIA, and
QUANTA Lite ANA Screen ELISA (which simultaneously
detects serum autoantibodies to common SARD-related
autoantigens), revealed that only 5.5 % of patients with
anti-DFS70/LEDGFp75 antibodies had SARD. Most of the
anti-DFS70/LEDGFp75 antibody-positive samples were
negative on the ANA Screen ELISA. When combining a
negative ANA ELISA result with a positive anti-DFS70/
LEDGFp75 antibody test result, good discrimination
between SARD and non-SARD patients was obtained [24],
strengthening the notion that when found as the only ANA-
IIF specificity in patient serum this antibody could serve as
a reliable exclusion marker of SARD.
Fitch-Rogalsky et al. [130] analyzed the clinical and
serological features of patients referred through a
rheumatology central triage system because of a positive
ANA test. Of 15,357 referred patients, 4.1 % had positive
ANA. The frequency of the anti-DFS70/LEDGFp75
autoantibody in 225 archived sera from the patients eval-
uated by a rheumatologist was 15.1 %, and this was the
sole autoantibody in 70.6 % of the anti-DFS70/
LEDGFp75-positive patient sub-cohort. Among the anti-
DFS70/LEDGFp75-positive patients, 6 % had SARD with
other autoantibodies. This reinforced the notion that when
these autoantibodies are present in patients with SARD
they usually coexist with other disease marker autoanti-
bodies and tend to exclude a SARD diagnosis when they
are the sole ANA-IIF specificity in human sera. The
detection of anti-DFS70/LEDGFp75 antibodies is now
used in this triage system to help prioritize patients for
referral and thereby reducing waiting times for urgent
cases.
Consequences of anti-DFS70/LEDGFp75
antibodies for ANA testing
Accurately identifying the DFS-IIF pattern by ANA-HEp-2
screening is not an easy task [22, 26, 107, 112, 131].
Bizzaro et al. [22, 112] noted that 86 % of moderate to
high-titer sera producing the DFS-IIF pattern in HEp-2
slides failed to recognize DFS70/LEDGFp75 in DFS70-
specific ELISA systems. In addition, analysis of these sera
in HEp-2 slides from various commercial sources gave
inconsistent results. These investigators attributed these
discrepancies to different HEp-2 substrate preparations, the
type of DFS70/LEDGFp75 epitope exposed in the ELISA
systems, and the identification of the DFS-IIF pattern by
non-expert clinical interpreters.
These concerns highlight the importance of accurately
identifying the anti-DFS70/LEDGFp75 antibodies using a
combination of detection methods that may include, in
addition to ANA-HEp-2, immunoblotting, DFS70-CIA,
and ELISA-DFS70, as well as expert interpretation of these
assays. The use of recombinant DFS70/LEDGFp75 pep-
tides encompassing the autoepitope region for autoanti-
body immunoadsorption is critical to validate the results [5,
6]. Fritzler [131] argued that inter-laboratory discrepancies
regarding detection of anti-DFS70/LEDGFp75 autoanti-
bodies during routine ANA screening could be rendered
moot by the availability of a second, validated test that
complements the ANA results. While this would be ideal,
the best practice for routine diagnostics would be a single,
well-characterized assay that has been widely validated in
various international laboratories.
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Another consideration is the possibility that nuclear
autoantigens other than DFS70/LEDGFp75 may also pro-
duce the DFS-IIF pattern. DFS70/LEDGFp75 is a com-
ponent of nucleoprotein complexes associated with
transcription regulation, and some of its interacting part-
ners co-localize with this protein, producing an identical
DFS-IIF pattern [42, 52–55].
Since ANAs are generally considered reliable
biomarkers for SARD and are included in the classification
criteria for SLE [132], ANA–HEp-2 testing outside a
proper clinical framework may yield a sizable portion of
ANA-positive individuals with no consistent evidence of
SARD [133]. This could cause undue concern and anxiety
in patients, their families and physicians alike, and even
lead to unwarranted therapeutic interventions [26, 133–
135]. This becomes even more crucial with compelling
evidence that autoantibodies may precede the clinical onset
of SARD by many years [127]. Not all sera demonstrating
the DFS-IIF pattern are from HI and it remains unclear
whether this staining pattern is universally recognized in
clinical diagnostic laboratories. The discrimination
between DFS-IIF pattern and the ‘‘quasi-homogeneous
pattern’’ might be challenging in routine diagnostic labo-
ratories [131]. This underlines the importance of a better
understanding of anti-DFS70/LEDGFp75 antibodies and
the inclusion of testing for these antibodies into diagnostic
algorithms [5, 6]. Sera with the DFS-IIF pattern should be
tested for anti-DFS70/LEDGFp75 antibodies using a
specific immunoassay and then the test results and their
significance clearly explained to patients [24].
Potential impact of anti-DFS70/LEDGFp75
antibodies on SLE classification criteria
A positive ANA test is part of the SLE criteria developed
by the American College of Rheumatology (ACR) and the
Systemic Lupus International Collaborating Clinics
(SLICC) [136, 137]. However, since anti-DFS70/
LEDGFp75 antibodies are not associated with SLE and
rarely found in isolation in SLE patients [3, 24, 26, 28, 107]
and could be confused with other ANA-IIF patterns [26],
these antibodies might reduce the specificity of the criteria.
Therefore, consideration should be given to the concept
that anti-DFS70/LEDGFp75 antibodies, when present as
the only ANA-IIF pattern in serum, could serve as an
exclusion criterion in the diagnosis and classification of
SLE. Thus, a revised ACR criterion #11 might state: ‘‘An
abnormal titer of antinuclear antibody by immunofluores-
cence, excluding monospecific anti-DFS70/LEDGFp75
reactivity, or an equivalent assay at any point in time and in
the absence of drugs.’’
What exactly are the anti-DFS70/LEDGFp75
autoantibodies trying to tell us?
Are these autoantibodies natural and protective?
Natural autoantibodies, both IgM and IgG, play a critical,
protective role by assisting in the clearance or neutraliza-
tion of apoptotic cell debris, which is essential to prevent
the release of intracellular self-antigens and danger signals
that could induce inflammatory and autoimmune responses
[137–140]. To date there is little objective and formal
evidence that anti-DFS70/LEDGFp75 autoantibodies are
natural antibodies playing protective roles. While their low
frequency in SARD, presence in 5–10 % of HI who do not
develop autoimmune conditions after years of follow-up,
and increased levels in DM-ILD patients who went into
remission after therapy, suggest the possibility that they
could play a protective role, further studies are warranted
to support this role. These autoantibodies might function in
the removal of DFS70/LEDGFp75 cleavage fragments
from debris generated during cell death associated with
tissue damage. This would not only attenuate local
inflammatory responses, but also prevent these fragments
from enhancing cell death [32].
Are these autoantibodies pathogenic?
The only evidence that these autoantibodies could play
pathogenic roles comes from the studies by Ayaki et al. [108,
111] reporting their cytotoxicity in vitro against LEC and
cultured lens organs. In this context, when upregulated and
activated by stress, DFS70/LEDGFp75 could be released into
the extracellular milieu and uptaken by cells in the local tissue
microenvironment where it may transcriptionally activate
stress response and pro-inflammatory pathways. Ayaki et al.
[108, 111] suggested that binding of the autoantibodies to
released DFS70/LEDGFp75 exerts a pathogenic role by pre-
venting its uptake by neighboring cells.
Are these autoantibodies sensors
of microenvironmental stress and inflammation?
The broad spectrum of diseases and conditions associated
with the presence of anti-DFS70/LEDGFp75 autoantibod-
ies (Table 3) points to an augmented state of cellular
oxidative stress, local inflammation, and tissue damage
(i.e., bladder, eye, skin, prostate), as potential common
denominators. Dying cells, which in vivo can be derived
from tissue damage, are a source of intracellular autoanti-
gens that are clustered in apoptotic blebs or post-transla-
tionally modified [141–143]. Defects in the clearance of
dying cells in certain autoimmune diseases or inflammatory
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conditions, associated with inflammatory necrosis or pro-
gression of apoptosis to secondary necrosis, could lead to a
pro-inflammatory environment, thus facilitating autoanti-
body responses to aberrantly modified autoantigens [144].
Primary and secondary necrosis, and necroptosis, also yield
unique autoantigen cleavage fragments, generated by
lysosomal cathepsins that are recognized by autoantibodies
[98, 145, 146].
As mentioned previously, DFS70/LEDGFp75 is cleaved
during apoptosis into fragments that are recognized by human
autoantibodies and that persist during secondary necrosis [32,
33, 98, 99]. Its overexpression in disease-affected tissues,
combined with its proteolytic cleavage or involvement in
stress-induced protein complexes that influence its processing
by the immune system, may alter its immunogenicity in a pro-
inflammatory microenvironment, making it a target of
autoantibodies (Fig. 4). There is evidence that tissue over-
expression, mutation, or posttranslational modification of
intracellular autoantigens in a pro-inflammatory context may
trigger the elicitation of autoantibodies [143, 145–147]. It is
then plausible that autoantibodies to DFS70/LEDGFp75
could then be considered as ‘‘sensors’’ of microenvironmental
stressors associated with inflammation, tissue damage, and
altered expression of this protein.
Conclusions
The answer to the question of what are the anti-DFS70/
LEDGFp75 autoantibodies trying to tell us, first posed by
our group a decade ago [8], still eludes the field of ANA
research. However, our current knowledge of the DFS70/
LEDGFp75 autoantigen-autoantibody system, reviewed
above, provides the following clues, which could help us
understand its biological and clinical significance:
1) DFS70/LEDGFp75 is a stress response transcription
co-activator that contributes to the upregulation of
stress protective and inflammatory genes, leading to
cellular survival under environmental stress in both
health and disease contexts.
2) Altered function, expression, or structure of DFS70/
LEDGFp75 in a microenvironment characterized by
inflammation and tissue damage may contribute to
disease pathogenesis and autoantibody elicitation.
3) Autoantibodies to DFS70/LEDGFp75 preferentially
target a functionally important and conserved region
in its C-terminal domain.
4) Anti-DFS70/LEDGFp75 IgG autoantibodies can be
found at high titers in apparently healthy individuals
Environmental Stressors
(xenobiotics, drugs, allergens, irradiation, infectious agents, pro-oxidants, unhealthy diet, etc)
Increased oxidative stress and inflammation 
Apoptosis and 
secondary necrosis under 
pro-inflammatory 
microenvironment
Loss of immune tolerance








Moderate cellular stress 
leading to cell survival
Severe cellular stress 
leading to cell death 
Fig. 4 Model for the elicitation
and role of anti-DFS70/
LEDGFp75 autoantibodies.
Environmental stressors may
induce oxidative stress and
inflammation in certain tissues,






response or its apoptotic
cleavage under tissue damage
and inflammation induced by
severe stress may alter its
immunogenicity, leading to the
elicitation of autoantibodies in
genetically susceptible
individuals
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and in patients with diverse, non-SARD, inflamma-
tory conditions.
5) When present in patients with SARD, anti-DFS70/
LEDGFp75 autoantibodies are usually accompanied
by SARD-marker antibodies.
6) Anti-DFS70/LEDGFp75 autoantibodies may serve as
exclusion markers of SARD when present as the only
ANA specificity in patient sera.
7) Detection of anti-DFS70/LEDGFp75 autoantibodies
by ANA-HEp-2 IIF test is not always reliable, and
positive tests should be confirmed using other
detection platforms.
We propose that depending on the context, anti-DFS70/
LEDGFp75 autoantibodies could serve as protective anti-
bodies with no specific disease relevance, pathogenic
antibodies in certain conditions, or sensors of increased
stress and inflammatory cellular damage in the local
microenvironment of the affected organ or tissue (Fig. 5).
It cannot be ruled out that the presence of these autoanti-
bodies could be an ‘‘epiphenomenon’’ unrelated to the
disease conditions listed in Table 3, and coincident as the
result of yet to be identified factors or co-morbid condi-
tions. The relatively low frequency (\15 %) of these
antibodies in most HI and patient cohorts evaluated for
their presence indicates that only certain individuals pro-
duce them, which points to genetic susceptibility in their
generation.
We recommend that comprehensive information on the
health history, lifestyle, ethnicity, geographic location, and
exposure to environmental stressors or xenobiotics should be
acquired for both HI and patients producing anti-DFS70/
LEDGFp75 autoantibodies. Initiatives such as the CARTa-
GENE biobank study [148], which seeks to identify genetic
and environmental factors associated with disease-related
quantitative traits, might help determine whether these
antibodies could be linked to specific geographic areas and/
or exposures that may influence the levels of oxidative stress
in a particular tissue microenvironment, leading to aberrant
DFS70/LEDGFp75 expression and autoantibody produc-
tion. We anticipate that as our knowledge of the DFS70/
LEDGFp75 autoantigen-autoantibody system advances, its
elusive biological and clinical significance will unravel,
leading to translational applications.
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